文献速递神经介入MRDSA

Shield技术Pipeline栓塞装置治疗未破裂动脉瘤的结局研究(PEDSU)

Outcome Study of the Pipeline Embolization Device with Shield Technology in Unruptured Aneurysms (PEDSU).
PubMed 文献 · AJNR Am J Neuroradiol · 2019-11-14

本研究评估第三代Pipeline Shield血流导向装置治疗未破裂动脉瘤的安全性和疗效,分析了2016年3月至2018年1月间44例手术(41例患者、44个靶动脉瘤、共52个动脉瘤)。1年累积死亡率和致残率分别为2.3%和6.8%,6个月和18个月充分闭塞率分别为78.8%和90.3%。作者认为其闭塞率和安全性结局与既往血流导向装置及早期Pipeline装置的研究相似。

要点

  • 随访用3D-TOF-MRA评估动脉瘤闭塞,6个月充分闭塞率78.8%、18个月90.3%。
  • 1年累积死亡率和致残率分别为2.3%和6.8%。
  • 88.5%装置置入前循环,11.5%置入后循环;囊状动脉瘤占94.2%。

核心结论

  • 在这项实用性、非企业资助的研究中,Pipeline Shield的闭塞率和安全性结局与既往血流导向装置及早期Pipeline栓塞装置的研究相似。

研究设计与样本

  • 研究类型为实用性、非企业资助的结局研究,分析2016年3月至2018年1月间实施的44例Pipeline Shield手术。
  • 样本为41例患者、44个靶动脉瘤,共治疗52个动脉瘤。
  • 随访采用3D-TOF-MRA评估动脉瘤闭塞,分析30天和1年死亡与致残率以及6个月和18个月影像学闭塞结局。

关键影像表现/征象

  • 88.5%的装置置入前循环,11.5%置入后循环。
  • 52个动脉瘤中囊状49个(94.2%)、梭形1个(1.9%)、医源性假性动脉瘤1个(1.9%)、夹层动脉瘤1个(1.9%)。
  • 囊状动脉瘤中宽颈(颈宽>4 mm)占71%(35/49),大型(≥10 mm)占34.6%(18/52),巨大型(≥25 mm)占3.8%(2/52)。
  • 动脉瘤囊最大径平均9.0 mm,颈宽平均5.0 mm。

诊断标准与关键数值

  • 充分闭塞率6个月为78.8%,18个月为90.3%。
  • 1年累积死亡率为2.3%,1年累积致残率为6.8%。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: The recently introduced Pipeline Flex Embolization Device with Shield Technology (Pipeline Shield) is the third generation of Pipeline flow-diverter devices. It has a new stent-surface modification, which reduces thrombogenicity. We aimed to evaluate clinical and radiographic (safety and efficacy) outcomes of the Pipeline Shield.

MATERIALS AND METHODS: The 30-day and 1-year mortality and morbidity rates and the 6- and 18-month radiographic aneurysm occlusion outcomes for procedures performed between March 2016 and January 2018 were analyzed. 3D-TOF-MRA was used for follow-up.

RESULTS: Forty-four attempted Pipeline Shield procedures were performed for 41 patients with 44 target aneurysms (total of 52 aneurysms treated). A total of 88.5% of devices were inserted in the anterior circulation, and 11.5%, in the posterior circulation; 49/52 (94.2%) aneurysms were saccular; and 1/52 (1.9%) was fusiform. One (1.9%) aneurysm was an iatrogenic pseudoaneurysm, and 1 (1.9%) was a dissecting aneurysm. Seventy-one percent (35/49) of the saccular aneurysms were wide-neck (neck, >4 mm), 34.6% (18/52) were large (≥10 mm), and 3.8% (2/52) were giant (≥25 mm). The mean aneurysm sac maximal diameter was 9.0 mm, and the mean neck width was 5.0 mm. The cumulative mortality and morbidity rates were 2.3% and 6.8% at 1 year, respectively. The adequate occlusion rate was 78.8% at 6 months and 90.3% at 18 months.

CONCLUSIONS: In this pragmatic and non-industry-sponsored study, the occlusion rates and safety outcomes were similar to those seen in previously published studies with flow-diverter devices and earlier generation Pipeline Embolization Devices.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Atasoy D, Kandasamy N, Hart J, et al. Outcome Study of the Pipeline Embolization Device with Shield Technology in Unruptured Aneurysms (PEDSU). AJNR Am J Neuroradiol. 2019. PMID: 31727754. doi:10.3174/ajnr.A6314

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。